Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Merck & Company Inc.

Dividend ETFs remain a go-to choice for investors seeking steady income. Two leading choices are the Schwab U.S. Dividend Equity ETF ($SCHD) and th...

VYMI vs. SCHD: Which Is the Best Dividend ETF for Passive Income?

Deutsche Bank analyst Falko Friedrichs maintained a Hold rating on Merck KGaA today and set a price target of €125.00. According to TipRanks, Fried...

Deutsche Bank  Remains a Hold on Merck KGaA (0O14)

Investors prefer exchange-traded funds (ETFs) for their ability to generate attractive returns while lowering risk through diversification. There a...

Best ETFs to Invest In, According to AI Analyst, 7/22/2026

UBS analyst Matthew Weston maintained a Buy rating on Merck KGaA today and set a price target of €150.00. According to TipRanks, Weston is a 4-star...

UBS Remains a Buy on Merck KGaA (0O14)

Merck ($MRK) shares rose over 3% on Thursday after the U.S. Food and Drug Administration approved LIPFENDRA, a new once‑daily pill that sharply low...

Merck (MRK) Rises after FDA Clears First Oral PCSK9 Cholesterol Pill

Exchange-traded funds (ETFs) are a popular investment choice to gain diversified exposure to a wide range of asset classes and markets. They offer ...

Best ETFs to Invest In, According to AI Analyst, 7/15/2026

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Merck & Company (MRK), Annexon Biosciences (ANNX) ...

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Annexon Biosciences (ANNX) and Guardant Health (GH)

Shares in Moderna ($MRNA) tumbled by 12% on Friday afternoon after JPMorgan ($JPM) reaffirmed its Sell rating on the U.S. pharma and biotech compan...

Here’s Why Moderna Stock (MRNA) Is Crashing Today — July 10, 2026

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cipher Pharmaceuticals (CPHRF), Invivyd (IVVD) and Merck & Compan...

Analysts Conflicted on These Healthcare Names: Cipher Pharmaceuticals (OtherCPHRF), Invivyd (IVVD) and Merck & Company (MRK)

In a report released yesterday, Trung Huynh from RBC Capital maintained a Buy rating on Merck & Company, with a price target of $142.00. Huynh cove...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MRK	$130.76	-0.24%	6.00M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MRK	$130.76	-0.2%	6.00M
3
4
5
6

MRK

MRK

Get Merck & Company Inc. Data in Excel

Get Merck & Company Inc. Data in Excel